Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Microsoft (MSFT) vs Nuvalent Inc (NUVL) Price & Performance

MicrosoftTrade
Nuvalent IncTrade

Price performance (Past 24H)

Key statistics

Microsoft vs Nuvalent Inc — how do they compare? Microsoft trades at $396.8 (market cap $2.99T), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Microsoft is far larger — about 304.8× Nuvalent Inc's market cap, and Microsoft pays a 0.9% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.

MSFTNUVL
Market Cap
$2.99T$9.81B
Volume
36,654,621
Sector
TechnologyTechnology
52-Week High
$542.07$123.96
52-Week Low
$352.83$72.16
Enterprise Value
$2.97T$8.52B
Dividend Yield
0.9%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Microsoft

Microsoft (MSFT) trades at $397.75, up 1.0% today, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $281.72B in 2025, with net income of $101.83B, and the company has beaten EPS estimates for three consecutive quarters. Analysts maintain an 80.49% buy rating with a consensus price target of $546.70, highlighting AI leadership through Azure and Copilot.

The outlook remains positive given robust earnings growth and AI-driven opportunities, but risks include elevated capital expenditure concerns and competitive pressures. Valuation metrics like a P/E of 23.96 and P/S of 9.43 suggest the stock is fairly priced, supporting a long-term bullish view tempered by near-term volatility.

Nuvalent Inc

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Microsoft

Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.

Read more on MSFT

About Nuvalent Inc

Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.

Read more on NUVL